Pensare (WRLS) Announces Business Combination with Computex
by Kristi Marvin on 2019-07-25 at 9:55am

Redeemers gonna redeem…(see “Quick Takes” below, as to why…)

Ahead of Pensare’s scheduled July 30th extension vote, Pensare Acquisition Corp. (WRLS), announced this morning that they have entered into a definitive agreement to combine with Stratos Management Systems, Inc. and its operating companies, which do business as Computex Technology Solutions (collectively, “Computex” or “Computex Technology Solutions”). Computex is an IT service provider offering a portfolio of managed IT services including Unified Communications-as-a-Service (UCaaS), directory and messaging services, enterprise networking, cybersecurity, collaboration, data center, integration, storage, backup, virtualization, and converged infrastructure.

Additionally, Pensare has also entered in a non-binding Letter of Intent (the “LOI”) to acquire an undisclosed developer of Unified Communications technology. The planned acquisitions are part of Pensare’s strategy to build a leading national Cloud-Managed Unified Communications and IT Solutions Provider. But wait…there’s more…

Pensare also announced that it has joined AT&T Partner Exchange®. Pensare can now bundle and resell AT&T network, mobility, IoT and cybersecurity solutions with its own services to serve as a one-stop-shop for business customers.

As for the transaction, we don’t have a filed presentation or a scheduled conference call, so the details provided are slim.  However, what we do know is that Pensare will acquire Computex for an aggregate of approximately $65 million in cash, stock, and assumed debt.  Additionally, Pensare would acquire the second target company for an aggregate of approximately $49.5 million in cash, stock, and assumed debt, pursuant to the LOI. Interestingly, the price per share for any Pensare stock issued to Computex’s shareholders will be either the lower of the market price per share or the lowest per share price paid in any PIPE’s Pensare completes in connection with the transaction (see “Quick Takes” for why).

Quick takes:  Not a whole lot of information on this transaction has been provided just yet, but this is presumably because Pensare has their extension vote next Tuesday, July 30th.  At that vote, Pensare will be asking for an additional four months to move their deadline to December 1, 2019, but have already stated that they DO NOT intend to contribute any additional funds to trust for shareholders who do not redeem. As a result, we can expect a significant number of redemptions. However, it sounds like that’s what Pensare wants, i.e., to reduce the trust amount and replace the shareholders with PIPE investors, albeit, done at a much lower effective share price.  This explains why the shares to be issued to Computex’s shareholders will be done “at either the lower of the market price per share or the lowest per share price paid in any PIPE’s Pensare completes in connection with the transaction.”  This is a nice way of saying, “we probably already have an idea of where this PIPE will be priced, but we don’t want to disclose it yet because it’s going to be below $10.00.”

So, as a result, we can probably expect a near complete redemption of the trust, a new PIPE to replace the cash, but done at a price below $10.00, and Rights holders will sell their converted shares into the market to drive the price down (and provide some much needed liquidity).  Remember, there will be an additional 3,105,000 shares added to the float once those Rights convert.  Pensare’s current estimated redemption value is approximately $10.44.

The transaction is expected to close in the fourth quarter of 2019.


THE TRANSACTION

  • Pensare will acquire Computex for an aggregate of approximately $65 million in cash, stock, and assumed debt
  • Pursuant to the terms of the LOI, it is proposed that Pensare would acquire the second target company for an aggregate of approximately $49.5 million in cash, stock, and assumed debt
  • The price per share for any Pensare stock issued to Computex’s shareholder would be the lower of the market price per share or the lowest per share price paid by any purchaser in any private placement effected by Pensare in connection with the transaction.
  • The transaction is expected to close in the fourth quarter of 2019.

ADVISORS

  • EarlyBirdCapital is serving as financial and capital markets advisor to Pensare.
  • Greenberg Traurig, LLP is acting as legal counsel to Pensare.
Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved